Stock listing

OTC:ACUT Accustem Sciences Inc Stock

Follow Accustem Sciences Inc into a list and get an email when it puts out news.

Share price · OTC:ACUT

$0.118 USD 0.000 (0.0%)

Close on Nov 18, 2026

Past year -86.5% · daily closes, Nov 18, 2025 – Nov 18, 2026, adjusted for splits
Day range
$0.118 – $0.118 USDNov 18, 2026
Volume
100 sharesNov 18, 2026
Market cap
$1.90M USDAt the close on Nov 18, 2026 · price × 16.07M shares outstanding
52-week range
$0.117 – $0.998 USDLowest and highest trades, Nov 19, 2025 – Nov 18, 2026
Traded on an average day
$452 USDMedian day 49 shares · 26 days with no trades · last 3 months, Aug 18, 2026 – Nov 18, 2026
Accustem Sciences Inc logo

Daily closes

Last 3 months, Aug 18, 2026 – Nov 18, 2026 · OTC:ACUT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.1180.0000.0%$0.118$0.118$0.118100
$0.118-0.012-9.2%$0.126$0.126$0.118610
$0.130-0.007-5.0%$0.130$0.130$0.1301,581
$0.137+0.007+5.3%$0.137$0.137$0.137125
$0.1300.0000.0%$0.130$0.130$0.130309
$0.130-0.013-9.0%$0.130$0.130$0.130250
$0.143-0.007-4.7%$0.143$0.143$0.143630
$0.150+0.020+15.4%$0.150$0.150$0.1504
$0.130-0.020-13.3%$0.130$0.130$0.130300
$0.1500.0000.0%$0.150$0.150$0.1500
$0.150-0.005-3.2%$0.136$0.150$0.1365,110
$0.155+0.021+15.9%$0.155$0.160$0.15516,997
$0.134-0.014-9.4%$0.134$0.134$0.134356
$0.1480.0000.0%$0.148$0.148$0.1480
$0.1480.0000.0%$0.148$0.148$0.1480
$0.1480.0000.0%$0.148$0.148$0.1480
$0.1480.0000.0%$0.148$0.148$0.1480
$0.1480.0000.0%$0.148$0.148$0.1480
$0.1480.0000.0%$0.148$0.148$0.1480
$0.148-0.003-1.7%$0.160$0.160$0.14812,826
$0.150+0.010+7.1%$0.150$0.150$0.1501,584
$0.140+0.005+3.7%$0.150$0.150$0.140257
$0.1350.0000.0%$0.135$0.135$0.1351,069
$0.1350.0000.0%$0.135$0.135$0.1350
$0.1350.0000.0%$0.135$0.135$0.1350
$0.1350.0000.0%$0.135$0.135$0.1350
$0.135+0.015+12.5%$0.135$0.135$0.1351,193
$0.1200.0000.0%$0.120$0.120$0.1200
$0.1200.0000.0%$0.120$0.120$0.1200
$0.1200.0000.0%$0.120$0.120$0.1200
$0.1200.0000.0%$0.120$0.120$0.1200
$0.120+0.003+2.6%$0.120$0.120$0.120401
$0.117-0.013-10.1%$0.139$0.139$0.117482
$0.1300.0000.0%$0.130$0.130$0.1300
$0.1300.0000.0%$0.130$0.130$0.1300
$0.1300.0000.0%$0.130$0.130$0.13049
$0.130-0.006-4.3%$0.130$0.130$0.13015,062
$0.136-0.016-10.5%$0.161$0.161$0.13620,112
$0.152-0.013-8.0%$0.170$0.170$0.15214,894
$0.165-0.015-8.2%$0.165$0.165$0.165106
$0.180+0.020+12.5%$0.181$0.181$0.1738,972
$0.1600.0000.0%$0.160$0.160$0.1600
$0.1600.0000.0%$0.160$0.185$0.160110
$0.1600.0000.0%$0.160$0.160$0.1600
$0.1600.0000.0%$0.160$0.160$0.160300
$0.1600.0000.0%$0.160$0.160$0.1600
$0.1600.0000.0%$0.160$0.160$0.1600
$0.1600.0000.0%$0.160$0.160$0.1600
$0.1600.0000.0%$0.160$0.160$0.1600
$0.1600.0000.0%$0.160$0.160$0.16010
$0.1600.0000.0%$0.160$0.160$0.1600
$0.1600.0000.0%$0.160$0.160$0.1600
$0.1600.0000.0%$0.160$0.160$0.1600
$0.160-0.065-28.9%$0.230$0.230$0.16041,517
$0.2250.0000.0%$0.225$0.225$0.2250
$0.225-0.015-6.2%$0.225$0.225$0.22014,606
$0.240+0.001+0.4%$0.222$0.240$0.2222,615
Ticker
OTC:ACUT
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
OTC
Currency
USD

What changed lately

Accustem Sciences Inc on 6ix

Sector
Health care
Industry
Diagnostics & research services
Decks
7 decks · latest Sep 30, 2026

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 18, 2026

Enterprise value
$1.88M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
0.19

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Accustem Sciences Inc · OTC:ACUTUS$1.90MUS$1.88Mn/an/an/an/an/an/a0.19
Telo Genomics Corp. · TSXV:TELOUS$2.80MUS$2.12Mn/an/an/an/an/an/a0.04
Advanced Biomed Inc. · NASDAQ:ADVBUS$2.73MUS$3.12M0.5×12.2×n/a0.2×n/a0.1×0.35
Innovotech Inc. · TSXV:IOTUS$2.66MUS$2.51Mn/a1.0×n/a1.5×−21.1%0.1×0.39
Qlife Holding AB · OMXSTO:QLIFEUS$2.49MUS$2.88Mn/a34.1×n/a9.6×n/a3.1×n/a
Physiomics PLC · LSE:PYCUS$2.46MUS$1.91Mn/a1.6×n/a3.6×−74.1%0.0×n/a
20/20 BioLabs, Inc. · NASDAQ:AIDXUS$2.10M−US$1.01Mn/a−0.5×n/a3.4×−317.8%0.9×1.41
Bluejay Diagnostics, Inc. · NASDAQ:BJDXUS$1.90M−US$5.43Mn/an/an/a0.3×n/a0.0×1.71
InVitro International · OTC:IVROUS$1.87MUS$644,26029.6×0.8×14.0×1.1×8.2%0.0×0.17
Co-Diagnostics, Inc. · NASDAQ:CODXUS$1.36MUS$2.21Mn/a2.6×n/a0.1×n/a0.2×2.16
Prostatype Genomics AB · OMXSTO:PROGENUS$1.36MUS$1.32Mn/a13.3×n/a2.1×n/a0.0×n/a
Median of the othersUS$2.28MUS$2.02M15.1×2.1×14.0×1.5×−47.6%0.1×0.39

Team and board

Officers

OfficerRole
Wendy BlosserChief Executive Officer
Jeff FenstererChief Operations Officer
Joe FlanaganChief Business Officer
Keeren ShahChief Finance Officer

Board

DirectorRole
Gabriele CerroneBoard Member
John BrancaccioBoard Member
Sean McDonaldBoard Member
Willy SimonBoard Member

Events

QuarterResultsShare move
Q2 2024Sep 16, 2024 · Before open+30.1%
Q1 2024May 20, 2024 · Before open+13.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck15 slidesSep 30, 2026
Investor Presentation (February 2026)Investor deck16 slidesFeb 18, 2026
Investor Presentation (September 2025)Investor deck18 slidesSep 18, 2025
Investor Presentation (October 2023)Investor deck16 slidesOctober 2023
Investor Presentation (June 2023)Investor deck17 slidesJun 8, 2023
Investor Presentation (May 2023)Investor deck21 slidesMay 23, 2023
Investor Presentation (December 2022)Investor deck19 slidesDec 1, 2022

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021
Research and development281.0K138.3K139.7K266.9K73.3K
Operating income-1.76M-1.51M-2.05M-3.75M-670.6K
Depreciation and amortization4183.63K3.63K3.32K
EBITDA-1.76M-1.50M-2.05M-3.74M
Income before tax-1.76M-1.51M-2.05M-3.75M-670.6K
Net income-1.76M-1.51M-2.05M-3.75M-670.6K
Earnings per share, basic-0.12-0.13-0.18-0.34-0.07
Earnings per share, diluted-0.12-0.13-0.18-0.34

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021
Cash and equivalents13.9K5.05K21.5K734.0K
Current assets49.4K50.4K129.8K932.0K1.35M
Property, plant and equipment4184.05K7.68K
Total assets1.55M50.9K133.9K939.7K1.35M
Accounts payable703.8K804.6K578.4K311.8K388.7K
Current liabilities4.95M3.36M2.25M1.08M702.7K
Total liabilities4.95M3.36M2.25M1.08M702.7K
Shareholders' equity-3.40M-3.31M-2.11M-139.6K650.7K
Shares outstanding16.1M12.1M11.3M11.3M10.00M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-850.4K-664.1K-1.62M-1.81M
Capital spending-11.0K
Free cash flow-1.82M
Cash from investing-11.0K
Cash from financing859.3K647.6K903.1K2.55M
Change in cash8.88K-16.4K-712.5K734.0K

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 20, 2026Quarterly reportSEC
NT 10-Q · Late filing noticeNov 16, 2026Explanation requestSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
10-K · Annual reportApr 14, 2026Annual reportSEC
NT 10-K · Late filing noticeMar 31, 2026Explanation requestSEC
8-K · Current reportNov 26, 2025Current reportSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
All 78 filings
FilingDateTypeFiled with
4 · Change in ownershipJun 13, 2025Insider tradeSEC
10-Q · Quarterly reportMay 20, 2025Quarterly reportSEC
NT 10-Q · Late filing noticeMay 15, 2025Explanation requestSEC
4 · Change in ownershipApr 10, 2025Insider tradeSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
10-K · Annual reportApr 3, 2025Annual reportSEC
NT 10-K · Late filing noticeMar 31, 2025Explanation requestSEC
SEC STAFF ACTIONFeb 21, 2025Other filingsSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
8-K/A · Current report, amendedJan 2, 2025Current reportSEC
8-K · Current reportDec 30, 2024Current reportSEC
10-Q · Quarterly reportNov 18, 2024Quarterly reportSEC
NT 10-Q · Late filing noticeNov 14, 2024Explanation requestSEC
10-Q · Quarterly reportSep 16, 2024Quarterly reportSEC
NT 10-Q · Late filing noticeAug 14, 2024Explanation requestSEC
10-Q · Quarterly reportMay 20, 2024Quarterly reportSEC
NT 10-Q · Late filing noticeMay 15, 2024Explanation requestSEC
8-K · Current reportApr 10, 2024Current reportSEC
10-K · Annual reportMar 22, 2024Annual reportSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
8-K · Current reportJun 9, 2023Management or board changeSEC
8-K · Current reportJun 6, 2023Current reportSEC
10-Q · Quarterly reportMay 5, 2023Quarterly reportSEC
10-K/A · Annual report, amendedApr 28, 2023Annual reportSEC
10-K · Annual reportFeb 15, 2023Annual reportSEC
S-1/A · Registration statement, amendedJan 19, 2023Offer documentSEC
4 · Change in ownershipJan 3, 2023Insider tradeSEC
4 · Change in ownershipDec 5, 2022Insider tradeSEC
4 · Change in ownershipNov 22, 2022Insider tradeSEC
S-1 · Registration statementNov 17, 2022Offer documentSEC
8-K · Current reportNov 16, 2022Management or board changeSEC
10-Q · Quarterly reportNov 8, 2022Quarterly reportSEC
8-K · Current reportOct 14, 2022Meeting outcomeSEC
DEFA14A · Additional proxy materialOct 11, 2022Meeting noticeSEC
DEF 14A · Proxy statementSep 14, 2022Meeting noticeSEC
PRE 14A · Preliminary proxy statementSep 2, 2022Meeting noticeSEC
10-Q · Quarterly reportAug 12, 2022Quarterly reportSEC
4 · Change in ownershipAug 2, 2022Insider tradeSEC
DRS · Draft registration statementJul 29, 2022Offer documentSEC
8-K · Current reportJun 21, 2022Management or board changeSEC
4 · Change in ownershipJun 9, 2022Insider tradeSEC
3 · Initial statement of ownershipMay 27, 2022Insider tradeSEC
3 · Initial statement of ownershipMay 27, 2022Insider tradeSEC
3 · Initial statement of ownershipMay 27, 2022Insider tradeSEC
10-Q · Quarterly reportMay 20, 2022Quarterly reportSEC
NT 10-Q · Late filing noticeMay 16, 2022Explanation requestSEC
4 · Change in ownershipApr 27, 2022Insider tradeSEC
10-K · Annual reportApr 18, 2022Annual reportSEC
8-K · Current reportApr 5, 2022Material contractSEC
NT 10-K · Late filing noticeMar 31, 2022Explanation requestSEC
8-K · Current reportMar 10, 2022Management or board changeSEC
3 · Initial statement of ownershipJan 14, 2022Insider tradeSEC
3 · Initial statement of ownershipDec 9, 2021Insider tradeSEC
3 · Initial statement of ownershipDec 3, 2021Insider tradeSEC
8-K · Current reportDec 3, 2021Acquisition or disposalSEC
EFFECT · Notice that a registration is effectiveJul 2, 2021Other filingsSEC
SEC STAFF ACTIONJul 1, 2021Other filingsSEC
F-6Jun 23, 2021Other filingsSEC
UPLOAD · Letter from the SECJun 7, 2021Other filingsSEC
CORRESP · Letter to the SECMay 28, 2021Other filingsSEC
20FR12G/AMay 28, 2021Other filingsSEC
UPLOAD · Letter from the SECMay 14, 2021Other filingsSEC
CORRESP · Letter to the SECMay 6, 2021Other filingsSEC
20FR12G/AMay 6, 2021Other filingsSEC
UPLOAD · Letter from the SECMay 3, 2021Other filingsSEC
UPLOAD · Letter from the SECApr 8, 2021Other filingsSEC
20FR12GMar 12, 2021Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Accustem Sciences Inc’s releases · as of Nov 20, 2026

Common shares
16,072,267
Fully diluted
16,072,267

Fully diluted

LineSharesAs of
Common shares16,072,267Nov 20, 2026

Share count over time

CountShares
Nov 20, 202616,072,267

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Gabriele CerroneBoard Member · Since at least Nov 5, 2026
Jeff FenstererChief Operations Officer · Since at least Nov 4, 2026
Joe FlanaganChief Business Officer · Since at least Nov 4, 2026
John BrancaccioBoard Member · Since at least Nov 5, 2026
Keeren ShahChief Finance Officer · Since at least Nov 5, 2026
Sean McDonaldBoard Member · Since at least Nov 5, 2026
Wendy BlosserChief Executive Officer · Since at least Nov 5, 2026
Willy SimonBoard Member · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Accustem Sciences Inc.